STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) SVP executes 10b5-1 stock sales and option exercises

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics SVP Finance Amy Bachrodt reported option exercises and share sales. On February 2, 2026, she exercised stock options for 4,844 and 156 shares of common stock at an exercise price of $10.42 per share.

That same day she sold 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305, and 736 shares at a weighted average price of $46.6323. The sales were effected under a Rule 10b5-1 trading plan. After these transactions, she directly owned 12,965 common shares, along with vested and vesting stock options.

Positive

  • None.

Negative

  • None.
Insider Bachrodt Amy
Role SVP, Finance
Sold 5,000 shs ($230K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 4,844 $0.00 --
Exercise Stock Option (Right to Buy) 156 $0.00 --
Exercise Common Stock 4,844 $10.42 $50K
Exercise Common Stock 156 $10.42 $2K
Sale Common Stock 200 $44.15 $9K
Sale Common Stock 4,064 $46.0305 $187K
Sale Common Stock 736 $46.6323 $34K
Holdings After Transaction: Stock Option (Right to Buy) — 3,025 shares (Direct); Common Stock — 17,809 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.345 to $46.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.365 to $47.23 per share, inclusive. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bachrodt Amy
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Finance
3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/02/2026 M(1) 4,844 A $10.42 17,809 D
Common Stock 02/02/2026 M(1) 156 A $10.42 17,965 D
Common Stock 02/02/2026 S(1) 200 D $44.15 17,765 D
Common Stock 02/02/2026 S(1) 4,064 D $46.0305(2) 13,701 D
Common Stock 02/02/2026 S(1) 736 D $46.6323(3) 12,965 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.42 02/02/2026 M(1) 4,844 (4) 02/17/2032 Common Stock 4,844 $0 3,025 D
Stock Option (Right to Buy) $10.42 02/02/2026 M(1) 156 (5) 12/08/2034 Common Stock 156 $0 41,333 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.345 to $46.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.365 to $47.23 per share, inclusive.
4. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026.
5. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Courtney Phillips, as attorney-in-fact 02/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider trades did MAZE SVP Finance Amy Bachrodt report on February 2, 2026?

Amy Bachrodt reported exercising stock options and selling Maze Therapeutics shares on February 2, 2026. She converted 4,844 and 156 options at $10.42 per share, then sold 200, 4,064, and 736 common shares at prices around the mid-$40s under a pre-arranged trading plan.

At what prices did MAZE executive Amy Bachrodt sell Maze Therapeutics common stock?

Amy Bachrodt sold Maze Therapeutics common stock at several prices on February 2, 2026. She sold 200 shares at $44.15, 4,064 shares at a weighted average of $46.0305, and 736 shares at a weighted average of $46.6323, reflecting multiple trades within specified price ranges.

How many Maze Therapeutics shares did Amy Bachrodt own after the reported Form 4 transactions?

After the reported transactions, Amy Bachrodt directly owned 12,965 shares of Maze Therapeutics common stock. In addition, she held stock options, including 3,025 options from a fully vested grant and 41,333 options from another grant that vests in monthly installments, subject to continued service.

Were the MAZE insider stock sales by Amy Bachrodt under a Rule 10b5-1 trading plan?

Yes, the reported sales were executed under a Rule 10b5-1 trading plan adopted by Amy Bachrodt. The plan was put in place on September 29, 2025, allowing pre-arranged trades to occur automatically according to preset instructions regardless of subsequent market or company developments.

What stock options did MAZE SVP Finance Amy Bachrodt exercise in this Form 4 filing?

Amy Bachrodt exercised two stock option grants. One option for 4,844 shares at a $10.42 exercise price was fully vested as of February 1, 2026. Another option for 156 shares at the same exercise price vests in 1/48th monthly installments beginning January 1, 2025, contingent on continued service.

How are the weighted average sale prices calculated in Amy Bachrodt’s MAZE Form 4?

The Form 4 states that certain prices are weighted averages across multiple trades. For example, shares sold at $46.0305 and $46.6323 represent aggregated prices for many trades between $45.345 and $47.23. Detailed per-trade pricing is available from the insider upon reasonable request.